Re-posted from the Canada Free Press By Lee Cary —— Bio and Archives—May 22, 2020

Somewhere along the way, two-thirds of America’s foundational trilogy of “Life, Liberty, and the Pursuit of Happiness” abdicated to the first third. So what happened?

The Virus

SARS-CoV-2, also known as the 2019 novel coronavirus, was shortened to COVID-19.  Or, to be politically incorrect, the Wuhan Virus or China Virus. And, for the very bold, the CCP (Chinese Communist Party) Virus.  SARS means “Severe Acute Respiratory Syndrome”.

SARS-CoV-1 was identified in 2003.  The search for a vaccine has been underway for 17 years.  SARS-CoV-1 is thought to have, perhaps, originated in bats. Perhaps, spread to cats. But surely, first infected humans in the Guangdong province of southern China in 2002.

SARS-CoV-2 is thought, maybe, to have a similar bat pedigree, but with a different point of Chinese entry that spread globally. Whether it was created in a lab, or in nature, is debated.

The Guardians of Public Health

The Centers for Disease Control and Prevention (CDC) “works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S.”  It opened on July 1, 1946 with 400 employees. In 2018, Forbesreported it had 10,639 “staffers”.

The National Institutes of Health (NIH), founded in the late 1880s, is “the primary agency of the United States government responsible for biomedical and public health research”.  In 2012, the NIH had 20,262 employees. More current numbers are unreported. Dr. Tony Fauci, age 79, has directed the NIH Institute of Allergy and Infectious Diseases since 1984.

Snapshot: “Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.”

Gilead News Highlights: 

August 2, 2012 – “Gilead Sciences inks deals with 3 Indian companies including Ranbaxy Laboratories for low-cost HIV drug” Then, nine months later…

May 13, 2013 – “Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA”

“Ranbaxy USA pleaded guilty to three felony FDCA [Food, Drug, and Cosmetic Act] counts, and four felony counts of knowingly making material false statements to the FDA [Food and Drug Administration]. The generic drugs at issue were manufactured at Ranbaxy’s facilities in Paonta Sahib and Dewas, India…[T]he whistleblower, Dinesh Thakur, a former Ranbaxy executive, will receive approximately $48.6 million from the federal share of the settlement amount. The case is U.S. ex rel. Thakur v. Ranbaxy Laboratories Limited, Case No. JFM-07-962 (D. Md.)”

Also reported, “FDA inspectors found tablets with a ‘black fibre’ suspected to be human hair and pills with apparent machinery oil ‘black spots’ at the Mohali plant.  Last year, glass was detected in some pills.”

On behalf of Gilead, Ranbaxy Labs cooked-up gnarly drugs.

August 4, 2014 – Two Gilead employees bring accusations against their employer in UNITED STATES OF AMERICA, ex. rel. CAMPIE et al., Plaintiffs, v. GILEAD SCIENCES, INC., et al., Defendants.

Jeffery Campie was Gilead’s Senior Director of Commercial Quality Assurance, and his wife Sherilyn Campie was an Associate Manager of Quality Control for Gilead.

The two claimed that Gilead had committed “violations of the False Claims Act (“FCA”), 31 U.S.C. § 3729, et. seq., and analogous state statutes and city ordinances, claiming that Gilead defrauded the federal, state, and local governments by selling billions of dollars’ worth of nonconforming drugs, which were paid for through programs like Medicare, Medicaid, and the President’s Emergency Plan for AIDS Relief [AKA: PEPFAR]”.

The pair stated that “…Gilead develops, manufactures, and sells drugs used to treat diseases like HIV/AIDS, hepatitis, and cystic fibrosis. Gilead manufactured and distributed drug products that failed to meet applicable specifications because they (1) were contaminated with a host of adulterants, including, but not limited to, arsenic, cadmium, mercury, lead, nickel, steel, titanium, chromium, iron, cobalt, aluminum, metal shards, glass, rubber, polyethylene (plastic), stones or pebbles, cement, paint, wood fibers and fibrous building materials, organic material, microbes (including bacillus cereus), paper, Teflon, acetaminophen, other degradants, and blood; (2) were improperly manufactured using active pharmaceutical ingredients (“API”) [the part of any drug that produces the intended effects] sourced on the cheap from unregistered facilities in China and otherwise in violation of federal law and Good Manufacturing Practices; (3) were subjected to extreme storage and shipping conditions; and (4) lacked proper testing and analysis…These nonconforming drugs were paid for by the government through programs like Medicare, Medicaid and the President’s Emergency Plan for AIDS Relief.”

November 6, 2019 – “United States Files Patent Infringement Lawsuit Against Gilead Related to Truvada and Descovy for Pre-exposure Prophylaxis of HIV.”

“In the complaint, HHS [U.S. Department of Health and Human Services] alleges that Gilead has willfully and deliberatively induced infringement of the HHS patents. The complaint further alleges that, as a result of such infringement, Gilead has profited from research funded by hundreds of millions of taxpayer dollars and reaped billions from PrEP [Pre-exposure prophylaxis when people at risk for HIV take daily medicine to prevent HIV] through the sale of Truvada and Descovy.”

In short, the U.S. Government (USG) claims that Gilead infringed upon USG patents by creating drugs that Gilead sold without rendering payment due to the USG for use of its patents. Furthermore, Gilead then sold some of those drugs to the USG.  I.e., a kind of double-dipping, or maybe straight theft.

Gilead Recycles Remdesivir

Gilead Sciences is the biopharmaceutical company that today markets Remdesivir. It’s the drug selected, by the government doctors in the white lab coats, to mitigate the symptoms of SARS-CoV-2. It was originally developed to treat Hepatitis C. When it was tested against the Ebola and Marburg virus diseases, it failed to work.

When SARS-CoV-2 came along, Remdesivir was taken off the shelf and used against SARS-CoV-2—not as a cure, but as a stopgap drug to mitigate symptoms. Hence, the Mayor of Los Angeles awaits a vaccine.

So, was all this the birth of a pandemic, born of a plandemic, or a child of both?

To be continued in Part 2 of “Pandemic, Plandemic, or Both?”